CVR number 31249791
Industry 86.9020 Other human health activities

JAMMERBUGT AUTORISEREDE FYSIOTERAPEUTER ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Bankruptcy risk for industry  0.6% 0.6% 0.6% 0.6% 0.6%  
Bankruptcy risk  1.0% 0.9% 2.1% 5.2% 5.6%  
Credit score (0-100)  88 88 66 42 40  
Credit rating  A A A BBB BBB  
Credit limit (kDKK)  143.8 95.3 0.1 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales  0 0 0 0 0  
Gross profit  1,695 1,868 1,711 1,917 1,916  
EBITDA  584 503 93.0 1,339 1,407  
EBIT  547 465 75.2 1,339 1,407  
Pre-tax profit (PTP)  508.2 449.5 65.7 1,331.0 1,404.1  
Net earnings  392.5 350.2 51.0 1,038.0 1,095.0  
Pre-tax profit without non-rec. items  508 450 65.7 1,331 1,404  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Tangible assets total  55.2 17.9 0.0 0.0 0.0  
Shareholders equity total  1,006 556 200 428 192  
Interest-bearing liabilities  386 148 326 0.0 44.0  
Balance sheet total (assets)  2,000 1,138 830 852 738  
Net Debt  -1,408 -328 -259 -522 -447  
 
See the entire balance sheet

Volume 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,695 1,868 1,711 1,917 1,916  
Gross profit growth  -17.3% 10.2% -8.4% 12.0% -0.0%  
Employees  5 5 5 3 3  
Employee growth %  66.7% 0.0% 0.0% -40.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,000 1,138 830 852 738  
Balance sheet change%  -63.6% -43.1% -27.1% 2.7% -13.4%  
Added value  584.2 502.6 93.0 1,356.4 1,406.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -446 -75 -36 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  32.3% 24.9% 4.4% 69.8% 73.4%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  14.6% 29.7% 7.8% 159.2% 177.0%  
ROI %  17.6% 44.1% 12.4% 280.7% 424.0%  
ROE %  37.0% 44.8% 13.5% 330.6% 353.5%  

Solidity 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Equity ratio %  50.3% 48.9% 24.1% 50.2% 26.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -241.0% -65.3% -277.8% -39.0% -31.8%  
Gearing %  38.4% 26.6% 162.9% 0.0% 23.0%  
Net interest  0 0 0 0 0  
Financing costs %  1.9% 5.9% 4.6% 4.6% 12.4%  

Liquidity 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Quick Ratio  2.0 2.4 1.4 6.5 3.1  
Current Ratio  2.0 2.4 1.4 6.5 3.1  
Cash and cash equivalent  1,794.4 476.5 584.3 521.7 490.7  

Capital use efficiency 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  961.2 648.0 218.4 720.8 500.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales / employee  0 0 0 0 0  
Added value / employee  117 101 19 452 469  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  117 101 19 446 469  
EBIT / employee  109 93 15 446 469  
Net earnings / employee  79 70 10 346 365